Fibromyalgia Health Center

Font Size
A
A
A

Naltrexone May Ease Fibromyalgia Symptoms

Preliminary Study Shows That Low-Dose Naltrexone May Be an Effective, Low-Cost Treatment for Fibromyalgia
By Miranda Hitti
WebMD Health News
Reviewed by Louise Chang, MD

April 17, 2009 -- An inexpensive drug called naltrexone may make a good treatment for fibromyalgia, report researchers at Stanford University.

Naltrexone isn't a new drug; it's been around for more than 30 years and is used to treat opioid addiction.

Stanford's Jarred Younger, PhD, and Sean Mackey, MD, PhD, tested a low dose of naltrexone as a fibromyalgia treatment in 10 women who had had fibromyalgia for about 10 years, on average.

First, the women spent two weeks recording the severity of their fibromyalgia symptoms every day using a handheld computer. And they took lab tests to gauge their fibromyalgia pain and sensitivity to heat and cold.

After that, the women took a placebo pill every day for two weeks, but they didn't know it was a placebo pill. At the end of the placebo period, the women took a naltrexone pill once a day for eight weeks. Finally, they spent the last two weeks of the study not taking naltrexone or the placebo.

All along, the women continued to rate their fibromyalgia symptoms every day, and they repeated their lab tests every two weeks.

While taking the placebo, the women reported a 2.3% drop in the severity of their fibromyalgia symptoms, compared to their symptom ratings at the start of the study.

When they switched from the placebo to naltrexone, they reported an additional 30% drop in their fibromyalgia symptom severity.

The women also showed greater tolerance for pain and for hot (but not cold) temperatures while taking naltrexone.

Most of the women -- six out of 10 -- responded to naltrexone.

Side effects were mild and brief.

Two women reported having more vivid dreams during the study, and one woman reported transient nausea and insomnia during the first few nights of taking the pills, note Younger and Mackey.

The study, which appears online in Pain Medicine, was a small, preliminary project to see if low-dose naltrexone showed promise. It did, so Younger and Mackey are already working on a new study that will test low-dose naltrexone in 30 fibromyalgia patients for 16 weeks.

chronic pain/back pain newsletter

Pain got you down? Don't suffer more than necessary. Sign up for WebMD's Chronic Pain/Back Pain newsletter and get the latest information on safe pain management.

webMD Video

Show or hide information about video: Trigger Point Therapy for Chronic Pain

  Trigger Point Therapy for Chronic Pain

Some physicians are prescribing trigger point therapy for chronic pain patients. It's an established technique that few people know about.

Watch Video: Trigger Point Therapy for Chronic Pain

 (opens in a new window)

Show or hide information about video: Frozen Shoulder   Frozen Shoulder

Show or hide information about video: Restless Legs Syndrome   Restless Legs Syndrome

Show or hide information about video: Healing Heel Pain   Healing Heel Pain

Show or hide information about video: Choosing a Mattress   Choosing a Mattress

Advertise on Fox News Channel, FOXNews.com and FOX News Radio Jobs at FOX News Channel. Internships at FOX News Channel (now accepting Fall interns).
Terms of use. Privacy Statement. For FOXNews.com comments write to foxnewsonline@foxnews.com; For FOX News Channel comments write to comments@foxnews.com
© Associated Press. All rights reserved.
SMARTMONEY ® © 2006 SmartMoney. SmartMoney is a joint publishing venture of Dow Jones & Company, Inc. and Hearst SM Partnership. All Rights Reserved.
All quotes delayed by 20 minutes. Delayed quotes provided by ComStock.
Historical prices and fundamental data provided by Hemscott, Inc.
Mutual fund data provided by Lipper. Mutual Fund NAVs are as of previous day's close.
Earnings estimates provided by Zacks Investment Research.
Upgrades and downgrades provided by Briefing.com.
This material may not be published, broadcast, rewritten, or redistributed. © 2006 FOX News Network, LLC. All rights reserved. All market data delayed 20 minutes.